KR20050074462A - N―치환 하이드로모르폰 및 그 용도 - Google Patents

N―치환 하이드로모르폰 및 그 용도 Download PDF

Info

Publication number
KR20050074462A
KR20050074462A KR1020057005255A KR20057005255A KR20050074462A KR 20050074462 A KR20050074462 A KR 20050074462A KR 1020057005255 A KR1020057005255 A KR 1020057005255A KR 20057005255 A KR20057005255 A KR 20057005255A KR 20050074462 A KR20050074462 A KR 20050074462A
Authority
KR
South Korea
Prior art keywords
compound
pain
compounds
formula
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057005255A
Other languages
English (en)
Korean (ko)
Inventor
도날드 제이 길리
Original Assignee
유로-셀티큐 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유로-셀티큐 에스.에이. filed Critical 유로-셀티큐 에스.에이.
Publication of KR20050074462A publication Critical patent/KR20050074462A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020057005255A 2002-09-25 2003-09-24 N―치환 하이드로모르폰 및 그 용도 Ceased KR20050074462A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41325402P 2002-09-25 2002-09-25
US60/413,254 2002-09-25

Publications (1)

Publication Number Publication Date
KR20050074462A true KR20050074462A (ko) 2005-07-18

Family

ID=32043224

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057005255A Ceased KR20050074462A (ko) 2002-09-25 2003-09-24 N―치환 하이드로모르폰 및 그 용도

Country Status (18)

Country Link
US (1) US6825205B2 (cg-RX-API-DMAC7.html)
EP (2) EP1803724A1 (cg-RX-API-DMAC7.html)
JP (2) JP4806190B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050074462A (cg-RX-API-DMAC7.html)
CN (1) CN100387600C (cg-RX-API-DMAC7.html)
AT (1) ATE360633T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003272642B2 (cg-RX-API-DMAC7.html)
BR (1) BR0314488A (cg-RX-API-DMAC7.html)
CA (1) CA2500118C (cg-RX-API-DMAC7.html)
CY (1) CY1106697T1 (cg-RX-API-DMAC7.html)
DE (1) DE60313478T2 (cg-RX-API-DMAC7.html)
DK (1) DK1543010T3 (cg-RX-API-DMAC7.html)
ES (1) ES2286461T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05003104A (cg-RX-API-DMAC7.html)
NZ (1) NZ538726A (cg-RX-API-DMAC7.html)
PT (1) PT1543010E (cg-RX-API-DMAC7.html)
WO (1) WO2004029059A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502174B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
EP2099764B1 (en) 2006-09-20 2011-07-27 Mallinckrodt Inc. Preparation of substituted morphinan-6-ones and salts and intermediates thereof
US20080234306A1 (en) * 2006-11-22 2008-09-25 Progenics Pharmaceuticals, Inc. N-Oxides of 4,5-Epoxy-Morphinanium Analogs
JP2010510329A (ja) * 2006-11-22 2010-04-02 プロジェニックス ファーマスーティカルス インコーポレーテッド 7,8−飽和−4,5−エポキシ−モルフィナニウム類似体
JP5875748B2 (ja) * 2007-03-06 2016-03-02 マリンクロッド エルエルシー 第4級n−アルキルモルフィナンアルカロイド塩の調製のための方法
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
WO2009023567A1 (en) * 2007-08-09 2009-02-19 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
CA2702680A1 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009070733A1 (en) * 2007-11-26 2009-06-04 Pharmacofore, Inc. Peripheral phenolic opioid antagonist
EP2896614B1 (en) 2008-05-27 2017-07-12 Mallinckrodt LLC Processes and compounds for the preparation of normorphinans
WO2010028004A2 (en) 2008-09-03 2010-03-11 Mallinckrodt Inc. Substituted berbines and processes for their synthesis
ME02367B (me) 2010-09-21 2016-06-20 Purdue Pharma Lp Analozi buprenorfina kao agonisti i/ili antagonisti opioidnog receptora
US10138207B2 (en) 2012-11-09 2018-11-27 Purdue Pharma, L.P. Benzomorphan analogs and the use thereof
EP2951160B1 (en) 2013-01-31 2019-04-24 Purdue Pharma LP Benzomorphan analogs and the use thereof
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
EP3087057A4 (en) 2013-12-26 2017-06-28 Purdue Pharma LP Ring-contracted morphinans and the use thereof
EP3087078B1 (en) 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3086790A4 (en) 2013-12-27 2017-07-19 Purdue Pharma LP 6-substituted and 7-substituted morphinan analogs and the use thereof
CA2950567A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
CA2951697A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
CN117567477B (zh) * 2023-11-15 2026-05-26 宜昌人福药业有限责任公司 一种氢吗啡酮和二氢吗啡类药物低分子聚乙二醇化物及其制备方法和应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3780819T2 (de) * 1987-09-10 1993-01-14 Univ Chicago Quaternaere derivate von noroxymorphon zur behandlung von uebelkeit und erbrechen.
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CN1535687A (zh) * 1996-11-25 2004-10-13 ������������ʽ���� 止痒药物
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan

Also Published As

Publication number Publication date
EP1543010A1 (en) 2005-06-22
WO2004029059A1 (en) 2004-04-08
PT1543010E (pt) 2007-07-26
DK1543010T3 (da) 2007-09-17
JP2006503850A (ja) 2006-02-02
JP4806190B2 (ja) 2011-11-02
DE60313478D1 (de) 2007-06-06
JP2011042681A (ja) 2011-03-03
CY1106697T1 (el) 2012-05-23
BR0314488A (pt) 2005-08-02
CA2500118C (en) 2011-04-12
CA2500118A1 (en) 2004-04-08
HK1080456A1 (en) 2006-04-28
US20040067973A1 (en) 2004-04-08
EP1543010B1 (en) 2007-04-25
NZ538726A (en) 2006-11-30
EP1803724A1 (en) 2007-07-04
US6825205B2 (en) 2004-11-30
DE60313478T2 (de) 2008-01-03
CN1684967A (zh) 2005-10-19
MXPA05003104A (es) 2005-05-27
CN100387600C (zh) 2008-05-14
ATE360633T1 (de) 2007-05-15
ZA200502174B (en) 2006-05-31
ES2286461T3 (es) 2007-12-01
AU2003272642B2 (en) 2009-07-09
AU2003272642A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
EP1543010B1 (en) N-substituted hydromorphones and the use thereof
Zimmerman et al. Discovery of a potent, peripherally selective trans-3, 4-dimethyl-4-(3-hydroxyphenyl) piperidine opioid antagonist for the treatment of gastrointestinal motility disorders
Bodor et al. Improved delivery through biological membranes. 13. Brain-specific delivery of dopamine with a dihydropyridine. dblharw. pyridinium salt type redox delivery system
SK3612000A3 (en) Sustained release tablet formulation to treat parkinson disease
RU2306314C2 (ru) Производные 6-амино-морфинана и их применение
CN118556058A (zh) 新方法
US20040122230A1 (en) Opiate analogs selective for the delta -opioid receptor
CN110709397A (zh) (+)-α-二氢丁苯那嗪琥珀酸盐
EP3822252A1 (en) Composition of fused tricyclic gamma-amino acid derivative and preparation therefor
EP4501929A1 (en) P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof
JP2004508272A (ja) アセチルコリンエンハンサー
SK15002000A3 (sk) Oxazolchinolónové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie na inhibíciu mrp1 u cicavcov
EP0489767B1 (en) Cck antagonists
RU2272027C2 (ru) Производные 3-гидроксипиперидина и фармацевтическая композиция на их основе
HK24194A (en) Pyrrolo[1,2-a][4,1]benzoxazepines, process for their preparation, pharmaceutical compositions containing these compounds and therapeutical use
HK1080456B (en) N-substituted hydromorphones and the use thereof
PT85593B (pt) Processo para a preparacao de hexa-hidro-arilquinolizinas substituidas
Matthews et al. Pyrazinobenzodiazepines as potent nonpeptide vasopressin receptor antagonists
SK8792002A3 (en) Quinoline-based compound, pharmaceutical composition containing same and use thereof
WO2018090360A1 (zh) 一种三芳基二甲基哌嗪二盐酸盐的多晶型物及其制备方法和应用
NZ208629A (en) Methyll evallorphanium salts and pharmaceutical compositions
JPH06184163A (ja) 1N−置換 ピラジノ〔2,3−c〕−1,2,6−チアジアジン 2,2−ジオキシド誘導体類、その製造方法及び薬剤調合物
JPWO1994016702A1 (ja) 便通異常の治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050325

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080910

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101102

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110907

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120403

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110907

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20101102

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I